Low Anterior Resection Syndrome Clinical Trial
Official title:
A Phase II Study of Sacral Nerve Stimulation for Low Anterior Resection Syndrome or Fecal Incontinence in Patients Following a Low Anterior Resection or Proctectomy With Coloanal Anastomosis or in Patients After Pelvic Chemoradiation (RESTORE)
Verified date | July 2023 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to nearby tissues or lymph nodes, or other pelvic cancer. Sacral nerve stimulation is a permanent implant that may improve bowel functions by stimulating the nerves that control the muscles related to bowel function.
Status | Terminated |
Enrollment | 3 |
Est. completion date | September 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Cohort 1: Patients with pathologically proven diagnosis of primary rectal cancer - Cohort 1: Patients who have previously undergone surgical resection and anastomosis (restorative) with curative intent treatment with or without chemoradiation - Cohort 1: Patients treated with restorative surgical resection without radiation - Cohort 1: Patients with any T-stage or N-stage rectal cancer that underwent treatment with radiation and restorative surgery - Cohort 1: Patients with self-reported FI or LARS - Cohort 1: Patients must be at least 18 years old and be able to speak and understand English - Cohort 1: Patients must be willing to and able to sign an approved informed consent document - Cohort 1: Patients must be >= 24 months post-resection of rectal cancer - Cohort 1: Patients must have failed prior conservative measures such as Metamucil and motility medications and already been assessed and treated in a pelvic floor rehabilitation program (biofeedback) designed to treat FI and LARS, and continue to experience significant defecatory dysfunction, allowable per principal investigator (PI) discretion - Cohort 1: Patients must be willing and able to complete Patient Reported Outcomes Questionnaires for before device placement, during the testing phase following lead placement, and after implantation of the battery - Cohort 1: Patients must be willing and able to undergo elective ARM testing to objectively measure pelvic floor function - Cohort 1: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM - Cohort 2: Patients with pathologically proven malignancy of the pelvis, other than rectal cancer (e.g. prostate, bladder, anus, vagina, vulva, cervix, uterus, or ovary) - Cohort 2: Patients treated with standard of care radiation therapies without surgical resection - Cohort 2: Patients with self-reported FI or other defecatory dysfunction - Cohort 2: Patients must be at least 18 years old and be able to speak and understand English - Cohort 2: Patients must be willing to and able to sign an approved informed consent document - Cohort 2: Patients must be >= 18 months post-pelvic chemoradiation - Cohort 2: Patients must have already been assessed and treated in a pelvic floor rehabilitation program design to treat FI or other defecatory dysfunction and continue to experience significant defecatory dysfunction - Cohort 2: Patients must be willing and able to complete Patient Reported Outcomes (PROs) and bowel and bladder diaries (Medtronic) at multiple times during the study - Cohort 2: Patients must be willing and able to undergo elective ARM testing to measure pelvic floor function - Cohort 2: Patients who have an average resting tone < 40 mmHg (normal > 40 mmHg) and maximal tolerance < 200 milliliters (normal 200-300 milliliters) as measured by ARM Exclusion Criteria: - Cohort 1: Patients with co-morbid illnesses or concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Cohort 1: Any diverting bowel ostomy at the time of consent to this study - Cohort 1: Patients with an absolute neutrophil count (ANC) < 1.7 within 30 days of consent - Cohort 1: Patients with an international normalized rate (INR) > 1.3 within 30 days of consent - Cohort 1: Patients with a platelet count < 50 K within 30 days of consent - Cohort 1: Patients currently being treated with chemotherapy or within preceding 30 days at the time consent - Cohort 1: Patients previously treated with a SNS for urinary or FI - Cohort 1: Patients who were documented to have an anastomotic leak following their restorative surgical resection - Cohort 1: Patients with an Eastern Cooperative Oncology Group (ECOG) performance status > 2 at the time of consent - Cohort 1: Patients with an active infection requiring systemic therapy at the time of consent - Cohort 1: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure - Cohort 2: Co-morbid illnesses or other concurrent disease, which in the judgment of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Cohort 2: Patients with an ANC < 1.7 within 30 days of consent - Cohort 2: Patients with an INR > 1.3 within 30 days of consent - Cohort 2: Patients with a platelet count < 50 K, within 30 days of consent - Cohort 2: Patients currently being treated with chemotherapy or within the preceding 30 days at the time of consent - Cohort 2: Patients previously treated with a sacral nerve stimulator for urinary or fecal incontinence - Cohort 2: Patients with an ECOG performance status > 2 at the time of consent - Cohort 2: Patients with an active infection requiring systemic therapy at the time of consent - Cohort 2: Patients with a significant history of uncontrolled cardiac disease including, but not limited to hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure - Cohort 2: Patients with an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
United States | MD Anderson in Sugar Land | Sugar Land | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sacral Nerve Stimulation (SNS) Success | SNS success will be measured as a patient having the battery implanted at visit 3. Patients who do not have the SNS placed, for any reason other than insurance coverage issues, will count as not having a success. Fecal incontinence will be measured by the physician as the total number of gas, mucus, liquid stool, and solid stool accidental leakage events reported in the bowel diaries. Improvement will be determined by the physician based on bowel diary comparisons recorded before SNS lead placement at visit 1 to after lead placement at visit 2. The proportion of patients who experience SNS success will be reported with a 90% credible interval using a beta (1,1) | Up to visit 3 | |
Secondary | Fecal Incontinence Severity Index Questionnaire Summary | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Fecal Incontinence Quality of Life Questionnaire Summary | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Euroqol-5 Dimensions-5 Levels (EQ-5D-5L) | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | International Consultation on Incontinence Society - Female Lower Urinary Tract Symptoms | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Memorial Sloan Kettering Cancer Center Bowel Function Questionnaire (BFQ) | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Low Anterior Resection Syndrome Score BFQ | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Cleveland Clinic Incontinence Score | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years | |
Secondary | Impact of SNS on Bowel Dysfunction | Will be measured using bowel diaries. | Up to 30 days (visit 2) | |
Secondary | Impact of SNS on Urinary Incontinence | Will be measured using bladder diaries and a post-void urinary bladder residual and validated urinary symptom questionnaire. | Up to 30 days (visit 2) | |
Secondary | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29 | Will be reported descriptively with graphs or tabulations for categorical survey outcomes. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04087421 -
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
|
Phase 3 | |
Recruiting |
NCT03828318 -
Impact of a Patient-Centered Program for Low Anterior Resection Syndrome A Multicenter Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04040842 -
International Low Anterior Resection Score Evaluation
|
||
Recruiting |
NCT04023448 -
The Effect of Different Reconstruction Methods on Anterior Resection Syndrome
|
N/A | |
Not yet recruiting |
NCT06424522 -
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
|
Early Phase 1 | |
Completed |
NCT05605600 -
Translation of the International Consensus Definition of LARS Into a Bowl Dysfunction Severity Scoring Tool (New LARS Score)
|
||
Completed |
NCT05016583 -
Paula Method of Exercises in Patients With LARS Syndrome
|
N/A | |
Active, not recruiting |
NCT05042700 -
The Effect of Melatonin in Patients With Low Anterior Resection Syndrome
|
Phase 2 | |
Recruiting |
NCT04612569 -
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
|
||
Completed |
NCT04896879 -
Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals Regarding LARS
|
||
Recruiting |
NCT06162143 -
Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome
|
||
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Completed |
NCT03916549 -
Acupuncture in Low Anterior Resection Syndrome Treatment
|
Phase 1 | |
Completed |
NCT05020132 -
Bowel Dysfunction After Rectal Cancer Treatment
|
||
Completed |
NCT03598231 -
Effectiveness of Sacral Neuromodulation in Low Anterior Resection Syndrome
|
N/A | |
Recruiting |
NCT05420870 -
Effect of Exercise on Bowel Function in Colorectal Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT05319054 -
Pathway of Low Anterior Resection Syndrome Relief After Surgery: a Feasibility Study
|
N/A | |
Completed |
NCT01589471 -
The Value of Botox-A for Management of Low Anterior Resection Syndrome
|
Phase 2 | |
Completed |
NCT03215017 -
Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery
|
N/A | |
Completed |
NCT05129215 -
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
|